Over the past 20 years, new insights into cardiovascular immunopathology have shifted the therapeutic focus from lipids to inflammation. In this Review, Duivenvoorden and colleagues discuss recent discoveries in the immunopathology of atherosclerosis, advances in bioengineering techniques, and how these advances have guided the development of innovative nanoimmunotherapeutic strategies to modulate immune responses in cardiovascular disease.
- Raphaël Duivenvoorden
- Max L. Senders
- Willem J. M. Mulder